Telehealth company eMed announced on Thursday that it has successfully raised $200 million in its latest funding round, pushing the Miami-based firm’s valuation beyond $2 billion. The company, which counts seven-time Super Bowl champion Tom Brady among its backers, collaborates with employers and government payers to manage the use of GLP-1 drugs, a category of medications for obesity and diabetes. These drugs have faced challenges in broader insurance coverage due to their high costs.
Several telehealth platforms are competing to capture a share of the rapidly expanding GLP-1 weight-loss market, which is projected to reach $150 billion in annual sales by the next decade. The funds from this Series A financing round, led by Aon Consulting, will be directed toward enhancing eMed’s agentic AI platform and bolstering its financial position as it prepares to introduce a novel healthcare payment model designed to reduce employer healthcare expenses.
Notable investors in this round include Tom Brady, who also serves as eMed’s founding chief wellness officer, CEO Linda Yaccarino, and Jeff Aronin, founder and CEO of Paragon Biosciences, among others. Established in 2020, eMed initially gained momentum during the COVID-19 pandemic by offering at-home testing kits and later expanded into diagnostics for strep throat and urinary tract infections, although it has since shifted focus away from these services.
In a significant development, CEO Linda Yaccarino, formerly the chief executive of social media platform X, emphasized that the funding round validates eMed’s growth trajectory and solidifies its position as a leader in population health. She highlighted the company’s mission to help employers control escalating healthcare costs and reverse the upward trend in expenses.
